More than half of epilepsies start before the age of 20 years and nearly 25% of them are refractory.
A tiny proportion of them are even labelled a "rare illness", i.e. one affecting less than 200,000 people in the United States or less than 5 out of 10,000 people in the European Union.
For these patients, two problems in their management arise:
Therefore, there are few drugs available.
However, a few target syndromes with a particularly unfavourable diagnosis. This work outlines 6 molecules in detail that are specifically used in epileptic encephalopathies. Every aspect of these molecules is discussed, including drug development, indication, efficacy, cost, etc.
Drafted by international experts in the field of epileptology, it provides all the necessary information on orphan drugs and their clinical use.
Editeur : John Libbey
Collection : Topics in Epilepsy
Publication : 22 septembre 2011
Edition : 1ère édition
Intérieur : Noir & blanc
Support(s) : Text (eye-readable) [PDF + ePub]
Contenu(s) : PDF, ePub
Protection(s) : Marquage social (PDF), Marquage social (ePub)
Taille(s) : 5,4 Mo (PDF), 5,1 Mo (ePub)
Langue(s) : Anglais
Code(s) CLIL : 3165
EAN13 Text (eye-readable) [PDF + ePub] : 9782742012374
EAN13 (papier) : 9782742008100